{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:15:15Z","timestamp":1791544515925,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaci.2025.07.033","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:28:57Z","timestamp":1756308537000},"page":"1650-1655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term prophylactic treatment with deucrictibant for angioedema due to acquired C1-inhibitor deficiency"],"prefix":"10.1016","volume":"156","author":[{"given":"Mats","family":"de Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy S.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e9 M.","family":"Fijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-3723","authenticated-orcid":false,"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.07.033_bib1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.07.033_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/all.13686","article-title":"Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency","volume":"74","author":"Levi","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.07.033_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jaip.2023.10.017","article-title":"Efficacy and safety of rituximab-based treatments in angioedema with acquired C1-inhibitor deficiency","volume":"12","author":"Kalmi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.07.033_bib4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaip.2016.12.032","article-title":"Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency","volume":"5","author":"Zanichelli","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.07.033_bib5","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jaip.2021.01.040","article-title":"Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency","volume":"9","author":"Belb\u00e9zier","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.07.033_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaip.2022.10.041","article-title":"Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency","volume":"11","author":"Suffritti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.07.033_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2024.03.007","article-title":"Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial","volume":"154","author":"Petersen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.07.033_bib8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the Angioedema Control Test (AECT)\u2014a patient-reported outcome instrument for assessing angioedema control","volume":"8","author":"Weller","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.07.033_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the Angioedema Quality of Life Questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.07.033_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaci.2025.07.033_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12295","article-title":"Sensitivity to change and minimal clinically important difference of the angioedema control test","volume":"13","author":"Fijen","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2025.07.033_bib12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.07.033_bib13","series-title":"R: a language and environment for statistical computing","year":"2020"},{"key":"10.1016\/j.jaci.2025.07.033_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.057","article-title":"Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: results of CHAPTER-1 phase 2 trial","volume":"153","author":"Riedl","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925008899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925008899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:39:07Z","timestamp":1780202347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925008899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0091674925008899"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.07.033","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term prophylactic treatment with deucrictibant for angioedema due to acquired C1-inhibitor deficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}